EMEA’s Lönngren warns of differences in drug advice

Thursday 10 September 2009

Regulators who strive to ensure the safety of medicines sometimes give different advice to companies developing drugs than do health technology assessment (HTA) bodies that rule on the cost effectiveness of the same drugs.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom